

Special Issue

CD24 - a Novel Target for Cancer Therapy and a Biomarker for Cancer Prediction

Message from the Guest Editors

CD24 is a small, glycoposphatidylinositol-anchored cell surface receptor with a diverse array of functions; when adaptive immunity, inflammation, autoimmunity and cancer are just some of them. In recent years, *CD24* gene has raised considerable interest in tumor biology and poor treatment outcome. It has been identified as a new prognostic factor, stem cell marker in the human neoplasm and a biomarker for early detection of cancer. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth, metastasis and chemo-resistant. The biology of CD24 is intriguing but still not completely understood. With this special issue on CD24, we wish to stimulate increased awareness of this tiny *gene* and summarize the major findings associated with CD24 to stimulate new ideas for further research that may reveal the underlying link among the diverse processes mediated by CD24. Therefore we are soliciting for new original and exciting manuscripts that will shed light on its crucial role and potential applications in pathological and healthy situations.

Guest Editors

Prof. Dr. Nadir Arber

The Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Dr. Shiran Shapira

The Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Deadline for manuscript submissions

closed (25 June 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/45252

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).